| Overview |
| bsm-52551R |
| APC (31A2) Monoclonal Antibody |
| WB, IHC-P, IF(ICC) |
| Human, Mouse |
| Specifications |
| Unconjugated |
| Rabbit |
| Human APC between 50-300 amino acids |
| Monoclonal |
| 31A2 |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
| Store at -20°C for 12 months. |
| Target |
| 324 |
| P25054 |
| Adenomatous polyposis coli protein, Deleted in polyposis 2.5, Protein APC, APC |
| Tumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. It is required for the localization of MACF1 to the cell membrane and this localization of MACF1 is critical for its function in microtubule stabilization. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(ICC) |
1:50-200 |
Powered by Bioz